Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. - Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Malandrakis P; Eleutherakis-Papaiakovou E; Papatheodorou A; Kanellias N; Migkou M; Fotiou D; Dialoupi I; Roussou M; Kokkali NA; et al. (Blood cancer journal, 2020)